The presence of the novel parvovirus PARV4 and a related variant, PARV5, was recently demonstrated in pooled plasma used in the manufacture of blood and plasma-derived medicinal products. DNA sequence analysis of nearly full-length genomes of four PARV4 and two PARV5 strains from manufacturing plasma pools is now presented. Like PARV4, PARV5 encodes two non-overlapping open reading frames (ORF1 and ORF2), homologous to the non-structural and capsid proteins of other parvoviruses, respectively. A highly conserved region in ORF2 contains phospholipase A 2 motifs involved in parvovirus infectivity. Hybridization of strand-specific probes to DNA extracted from high-titre, PARV4-positive plasma revealed that the positive and negative strands are packaged into PARV4 virions in similar quantities. This extended analysis of nearly full-length PARV4 and PARV5 sequences suggests that they are closely related genotypes and the use of a single virus name, PARV4, comprising genotypes 1 and 2 (previously termed PARV5) is proposed.
Parvoviruses are small, non-enveloped viruses containing linear, single-stranded DNA genomes. They infect a diverse range of vertebrate and invertebrate hosts. PARV4 is a novel human parvovirus recently identified in plasma from an intravenous drug user (IVDU) by using a sequenceindependent PCR amplification method (Jones et al., 2005) . This individual presented with symptoms of acute viral infection, including fatigue, vomiting, diarrhoea, sore throat, neck stiffness and joint pains, and was also coinfected with hepatitis B virus. Nothing is yet known about the role of PARV4 in human disease. DNA sequence analysis of the PARV4 genome identified two open reading frames, ORF1 and ORF2, with significant similarity to the non-structural and capsid proteins of parvoviruses, respectively. Phylogenetic analysis showed that PARV4 was distinct from other known animal or human parvoviruses (Jones et al., 2005) .
The prototype human parvovirus B19 (B19V) is a frequent contaminant of plasma pools used in the manufacture of plasma-derived medicinal products (reviewed by Brown et al., 2001; Laub & Strengers, 2002) . PARV4, and a related variant virus termed PARV5, have been identified in approximately 4-5 % of these manufacturing pools (Fryer et al., 2006 (Fryer et al., , 2007b . PARV4 and PARV5 were found to share 92 % nucleotide identity over a 178 bp region of ORF1. In the present study, more extensive sequence analysis has been performed on PARV4 and PARV5 strains identified in recent and older manufacturing plasma pool samples (Fryer et al., 2006 (Fryer et al., , 2007b . Strand-specific probes were used to analyse the packaging of the PARV4 genome.
Samples were screened for the presence of PARV4 and PARV5 DNA by using primers to ORF1 and/or ORF2, as described previously (Fryer et al., 2006 (Fryer et al., , 2007b , and nearly full-length PARV4 and PARV5 sequences determined in positive plasma pools. To avoid sequencing on different templates, two approximately 2.5-2.8 kb overlapping cDNA fragments spanning the ORF1 and ORF2 coding regions were amplified from extracted plasma samples. The 59 PARV4/5 fragment (nt 142-2977, GenBank accession no. AY622943) was amplified by using primers PARV4/ 5seq1 (59-CGGTCCCGCGAAAATTACGTATT-39) and PVORF2R (Fryer et al., 2007b) , whilst the 39 fragment (nt 2710-5247 of GenBank accession no. AY622943) was amplified by using primers PVORF2F (Fryer et al., 2007b) and PARV4/5seq21 (59-CGCGAAAATTGCGTATTTCCG-CT-39). The reaction mixture consisted of 16 Phusion HF Buffer (Finnzymes OY), 200 mmol each dNTP l 21 , 10 pmol each primer, 1 U proofreading Phusion Hot Start DNA Polymerase (Finnzymes OY) and 5 ml extracted DNA in a final volume of 50 ml. Thermal cycling was performed as follows: 98 u C for 10 s, followed by 45 cycles of 98 u C for 10 s, 63 u C for 30 s and 72 u C for 3 min. PCR products were purified, cloned into the pT7 Blue vector (Novagen) and both strands were sequenced as described previously (Fryer et al., 2006) . Sequences were assembled and ORFs were mapped by using the GCG software package, version 10.2 (University of Wisconsin). Comparisons of deduced protein sequences were performed by using BLAST (http:// www.ncbi.nlm.nih.gov/BLAST/). Phylogenetic analysis of nearly full-length PARV4 and PARV5 genomes was performed alongside full genome sequences of other members of the subfamily Parvovirinae (Lukashov & Goudsmit, 2001 ). Sequences were aligned by using CLUSTAL_W (Chenna et al., 2003) , and a neighbour-joining tree (nucleotide distance with Jukes-Cantor correction, pairwise gap deletion) with bootstrap resampling (100 replicates) was constructed by using MEGA3 software (Kumar et al., 2004) . Bootscan analysis was performed by using the SimPlot software, version 3.5.1 (Lole et al., 1999) .
For analysis of the encapsidation pattern of PARV4 virions, DNA was extracted from a high-titre PARV4-positive individual plasma donation and negative plasma controls as described above. This plasma sample was also positive for hepatitis C virus (HCV) RNA and was identified by a routine screening process to eliminate HCV-positive donations prior to the pooling of plasma for fractionation. Positive and negative plasmid controls were also tested. The PARV4-positive plasmid control contained a 1683 bp insert of PARV4 ORF2 (nt 1705-3387, GenBank accession no. AY622943). The PARV4-negative plasmid control contained a 1471 bp insert of PARV4 ORF1 (nt 603-2073 of AY622943). The PARV4 fragments were cloned into the vector pT7 Blue (Novagen) as described previously (Fryer et al., 2006) . All DNA samples were denatured with 0.25 M NaOH at 37 uC for 15 min prior to spotting onto a Hybond XL membrane (GE Healthcare). Nucleic acids were UV cross-linked. Membranes were pre-hybridized with Rapid-hyb buffer (GE Healthcare) in accordance with the manufacturer's instructions. Strand-specific probes were prepared by 59-end labelling of positive-and negative-sense oligonucleotides in ORF2 of PARV4 (PVORF2F and PVORF2R; Fryer et al., 2007b) by using [c-32 P]ATP and T4 polynucleotide kinase (TaKaRa) and used in accordance with the manufacturer's instructions. Replicate filters were hybridized at 42 u C with either the positive-or negativesense probes. Following hybridization, filters were washed at 42 u C with 0.16 SSC, 0.1 % SDS, in accordance with the manufacturer's instructions (GE Healthcare). Blots were quantified by using the InstantImager (Perkin Elmer) electronic autoradiography system.
Nearly full-length sequences (GenBank accession numbers indicated), comprising ORF1 and ORF2, were determined for the following strains of PARV4: BR10749-4 (DQ873386), BR11955-4 (DQ873388), A23-4 (DQ873389) and C51-4 (DQ873387); and for PARV5, BR10627-5 (DQ873390) and C25-5 (DQ873391). Strains BR10749-4 and BR10627-5 were identified in our preliminary study of manufacturing plasma pools (Fryer et al., 2006) , whilst the other strains were identified in further screening studies of plasma pools (Fryer et al., 2007b) . Strains BR10749-4, BR11955-4 and BR10627-5 were from plasma samples obtained between 2004 and 2005, whereas A23-4, C51-4 and C25-5 date from 1990-1993.
As with B19V, PARV4 and PARV5 genomes comprise two main ORFs: ORF1 (1992 nt, encoding 664 aa) and ORF2 (2745 nt, encoding 915 aa). However, unlike B19V, the two ORFs do not overlap and are separated by 103 and 106 nt for PARV4 and PARV5, respectively. By BLASTP analysis, PARV4 and PARV5 ORF1-encoded proteins are homologous to the non-structural protein of parvoviruses, NS1, showing greatest amino acid identity with NS1 of hamster (H-1) and goose parvoviruses (50 and 43 % identity, respectively). The amino acid sequence contains parvovirus-conserved motifs associated with rolling-circle replication [xuHuHuuux (aa 97-99) and uxxYuxxKxx (aa 157-161); Ding et al., 2002] and ATPase [A site GxxxxGK(T/S) (aa 334-341) and B site uuuu(D/E)(D/E) (aa 374-379); Astell et al., 1987; Ding et al., 2002] . The ORF2-encoded proteins are homologous to the viral capsid protein of parvoviruses, VP1, sharing approximately 45 and 41 % amino acid identity with VP1 of hamster parvovirus (H-1) and B19V-Au genotype 1, respectively. The amino acid sequence contains phospholipase A 2 motifs [YxGxG (aa 224-228) and HDxxY (aa 247-251], required for parvovirus infectivity (Zádori et al., 2001) . These motifs are completely conserved between PARV4 and PARV5.
Pairwise comparisons of each ORF of PARV4 and PARV5 strains indicate that ORF2 is more conserved than ORF1 (Table 1) , with most nucleotide differences limited to synonymous substitutions (91 % of nucleotide substitutions in ORF2 are synonymous, compared with 89 % in ORF1). Consequently, the amino acid sequences are more conserved, particularly for ORF2, suggesting that if PARV4 and PARV5 represent two distinct genotypes, they might be expected to represent a single serotype. This would be analogous to B19V genotypes 1-3, where serological crossreactivity has been demonstrated in vitro by using clinical sera against a genotype 2 virus isolate (Blümel et al., 2005) and baculovirus-expressed genotype 3 virus capsid antigens (Parsyan et al., 2006) . PARV4 sequences share approximately 98-100 % nucleotide identity with the original PARV4 isolate (GenBank accession no. AY622943), whilst PARV5 sequences share approximately 91-94 % nucleotide identity with the original PARV4 sequence (Table 1) . Sequence analysis indicates that there are two subgroups of PARV4, with a nucleotide divergence of 2 % between strains BR11955-4 and A23-4, and the prototype PARV4 sequence (GenBank accession no. AY622943). Overall, PARV4 and PARV5 strains share approximately 92 % nucleotide identity, similar to the level observed between B19V genotypes 1-3 (Servant et al., 2002; Gallinella et al., 2003) . Comparison of recent with archived strains within both PARV4 subgroups and PARV5 shows little evidence for evolutionary change over 10-15 years (99.8 % nucleotide identity over an approx. 4800-5000 bp region between recent and archived strains). This is in contrast to current evidence suggesting that carnivore and B19V parvoviruses exhibit a high rate of genetic change (Shackelton et al., 2005; Shackelton & Holmes, 2006) .
Although not based on full-length genomes, the current sequence analysis of PARV4 and PARV5 strains indicates that the two ends of the viral DNA are related by inverted terminal repeats (ITRs), as is the case for many parvoviruses. In the prototype PARV4 sequence (Jones et al., 2005 ; GenBank accession no. AY622943), nt 128-244 and 5151-5267 respectively correspond to incomplete 59 and 39 ITRs, possibly forming part of the stem structure of the hairpins, with nt 1-128 at the 59 end forming part of a loop structure (an axis of symmetry lies between nt 6 and 7). Incomplete ITRs obtained in this study are distinct between PARV4 and PARV5 (97-98 % nucleotide identity) and are slightly shorter than those of the original PARV4 sequence (GenBank accession no. AY622943), reflecting the length of the sequences obtained. Further sequencing of the ITRs has proved difficult, possibly due to the presence of repeated heptanucleotide sequences (CTTCCGG) identified in the hairpin stems of the original PARV4 sequence (GenBank accession no. AY622943), which are similar to those observed in the ITRs of goose and muscovy duck parvoviruses (Zádori et al., 1995) .
Phylogenetic analysis of PARV4 and PARV5 with other members of the subfamily Parvovirinae indicates that they are equidistant from human/primate autonomous parvoviruses and the adeno-associated (AAV)/avian viruses (Fig. 1a) . Based upon this nearly full-genome analysis, PARV4 and PARV5 are related most closely to porcine parvovirus 2 (PPV-2), a virus identified in swine sera from Myanmar (Hijikata et al., 2001) . Recombination analysis of the PARV4, PARV5 and PPV2 sequences indicates that these viruses do not appear to be recombinants of other known viruses (data not shown). Similarly, there was no evidence for recombination between PARV4 and PARV5, with the clustering pattern of all PARV4 and PARV5 strains being the same regardless of whether full-length sequences or individual ORFs were analysed. At the protein level, however, ORFs 1 and 2 of PARV4 and PARV5 showed closest amino acid identity to the non-structural and capsid proteins of hamster parvovirus H-1, a virus causing significant morbidity and mortality in neonatal hamsters (Besselsen et al., 1999) . Phylogenetic analysis again indicates that there are two subgroups of PARV4 (also indicated in Table 1 ); strains BR10749-4 and C51-4 cluster with the original PARV4 sequence (GenBank accession no. AY622943), whereas BR11955-4 and A23-4 represent a different subgroup. Phylogenetic analysis of non-synonymous substitutions also demonstrated that PARV4 and PARV5 sequences formed two separate clusters with bootstrap values of 98-100 % (data not shown). Nucleotide similarity plots along nearly full-length PARV4 and PARV5 sequences revealed a highly conserved region (.99 % nucleotide identity) between nt 2955 and 3420 (GenBank accession no. AY622943), located at the 59 end of ORF2 (Fig. 1b) . The phospholipase A 2 motifs, required for parvovirus infectivity, are located here. Based upon PARV4 and PARV5 sequence alignments of this region, we have designed a consensus real-time TaqMan PCR to quantify both PARV4 and PARV5 sequences (Fryer et al., 2007b) .
The encapsidation pattern of PARV4 was investigated by using strand-specific oligonucleotide probes to ORF2 and nucleic acid extracted from a high-titre PARV4-positive individual plasma donation. Both positive-and negativesense probes hybridized to the PARV4-positive plasma DNA (sample C, Fig. 2 ) and PARV4 ORF2 control plasmid DNA (Fig. 2, plasmid concentrations indicated) , but not to [2004] [2005] . dStrains derived from plasma pools from 1990-1993. (Hijikata et al., 2001) and human bocavirus (HBoVst1 and HBoVst2) (Allander et al., 2005) . B19V genotypes 1 (Shade et al., 1986) , 2 [A6 and LaLi (Nguyen et al., 2002; Hokynar et al., 2002) ] and 3 [V9 and D91.1 (Nguyen et al., 1999; Servant et al., 2002) ] are indicated. Virus names are given according to the ICTV nomenclature (Tattersall et al., 2005) , with GenBank accession numbers in parentheses. (b) Graphic representation of nucleotide similarity along nearly full-length sequences of PARV4 (grey lines) and PARV5 (black lines) strains, compared with the prototype PARV4 sequence (GenBank accession no. AY622943), using SimPlot. The coordinates for ORF1 and ORF2 are 283-2274 and 2378-5122 nt, respectively. Window, 200 bp; step, 20 bp; GapStrip, on; Kimura (two-parameter); T/t, 2.0.
PARV4 ORF1 control plasmid DNA (data not shown) or to human genomic DNA present in the plasma pools, even when levels were of the order of 10 6 copies ml 21 (sample B, Fig. 2 ). When the number of counts binding to the PARV4-positive plasma DNA sample was determined and compared with the respective plasmid control samples, it was found that the positive and negative strands were present in similar amounts. This packaging pattern is not characteristic of all parvovirus genera (Cotmore & Tattersall, 2006) . The availability of additional, nearly full-length sequences for PARV4 and the related variant PARV5 will assist in further phylogenetic studies and in the design of consensus and discriminatory assays. The recent finding that there are three distinct genotypes of B19V has led to a review of assays available for the detection and quantification of this virus (Baylis et al., 2004 (Baylis et al., , 2007 Hokynar et al., 2004) . In some cases, assays fail to detect the newly identified genotypes 2 and 3 of B19V, with consequent issues in terms of clinical diagnosis and viral load determinations in the plasma-fractionation setting, where it is a regulatory requirement to limit levels of B19V (Baylis et al., 2004) . The ability to design assays for PARV4 and PARV5 will assist in future studies to determine the role of these viruses in human disease. Nothing is yet known of the pathology associated with these viruses or whether PARV4 and PARV5 cause subclinical infections. However, PARV4 and PARV5 have been identified in plasma from healthy blood donors (Fryer et al., 2006 (Fryer et al., , 2007b with an increased incidence in febrile patients, including IVDUs and homosexual men (Fryer et al., 2007b) , and in HCV-infected individuals (including IVDUs) (Fryer et al., 2007a) . Phylogenetic analysis performed in this study shows that PARV4 and PARV5 cluster separately from each other, and could thus be considered as two genotypes of the same virus. We therefore propose the use of a single virus name, PARV4, comprising genotypes 1 and 2 (previously termed PARV5). Fig. 2 . Analysis of the packaging of the PARV4 genome. DNA from a high-titre PARV4-positive plasma sample was extracted, denatured, immobilized on a nylon membrane and probed with labelled, strand-specific oligonucleotide probes (F, forward; R, reverse) (C). DNA from PARV4-negative plasma (A, B) and PARV4 plasmid controls at 4¾10 7 , 4¾10 6 and 4¾10 5 copies per sample are shown.
